Adverse Events of the Duodenal-Jejunal Bypass Liner: a Systematic Review

Overview

Journal Obes Surg

Date 2018 Aug 20

PMID 30121857

Citations 16

Authors

Bark Betzel

Joost P H Drenth

Peter D Siersema

Affiliations

Soon will be listed here.

Abstract

A systematic review was conducted on adverse events (AEs) associated with the use of the duodenal-jejunal bypass liner (DJBL). PubMed, EMBASE, and Cochrane library were searched up to January 2018. The quality of reporting AEs was determined by the McHarm questionnaire and the risk of bias by the Newcastle-Ottawa scale. Thirty-eight studies were included. The comparability of the studies was low and the McHarm questionnaire showed incompleteness for most parameters in all studies. A total of 891 AEs were reported in 1056 patients. Thirty-three AEs (3.7%) were classified as severe, including hepatic abscess and esophageal perforation. The anchor of the DJBL caused or likely caused 85% of the SAEs. To improve the safety margin of the DJBL, adjustments to the anchoring system are needed.

Citing Articles

Role of endoscopic duodenojejunal bypass liner in obesity management and glycemic control.

Igi W, Oliveira V, Matar A, Hourneaux de Moura D Clin Endosc. 2024; 57(3):309-316.

PMID: 38356171 PMC: 11133994. DOI: 10.5946/ce.2023.217.

Overview on the endoscopic treatment for obesity: A review.

Abdulla M, Mohammed N, AlQamish J World J Gastroenterol. 2023; 29(40):5526-5542.

PMID: 37970474 PMC: 10642436. DOI: 10.3748/wjg.v29.i40.5526.

Research Progress of Duodenal-Jejunal Bypass Liner in the Treatment of Obesity and Type 2 Diabetes Mellitus.

Chen J, Yu Z, Liu Q, Meng Q, Chen X Diabetes Metab Syndr Obes. 2022; 15:3319-3327.

PMID: 36329806 PMC: 9624146. DOI: 10.2147/DMSO.S382324.

Endoscopic Bariatric and Metabolic Therapies for Liver Disease: Mechanisms, Benefits, and Associated Risks.

Ren M, Zhou X, Lv L, Ji F J Clin Transl Hepatol. 2022; 10(5):986-994.

PMID: 36304503 PMC: 9547260. DOI: 10.14218/JCTH.2021.00448.

Effect of Novel Gastro-Duodenal Flow Restrictor on Relative Weight Loss and Glucose Levels in a Porcine Model: A Pilot Randomized Study.

Huh G, Kwon J, Kim S, Lim H, Min S, Park D Nutrients. 2022; 14(13).

PMID: 35807743 PMC: 9268118. DOI: 10.3390/nu14132563.

References

Abu Dayyeh B, Edmundowicz S, Jonnalagadda S, Kumar N, Larsen M, Sullivan S . Endoscopic bariatric therapies. Gastrointest Endosc. 2015; 81(5):1073-86. DOI: 10.1016/j.gie.2015.02.023. View

Kato H, Kawamoto H, Matsumoto K, Moriyama I, Kamada H, Tsutsumi K . Outcome of self-expandable metallic stent deployment in patients with malignant gastroduodenal outlet obstruction and Niti-S and WallFlex comparison: a multicenter retrospective clinical study. J Dig Dis. 2016; 17(8):518-525. DOI: 10.1111/1751-2980.12377. View

De Luca M, Angrisani L, Himpens J, Busetto L, Scopinaro N, Weiner R . Indications for Surgery for Obesity and Weight-Related Diseases: Position Statements from the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO). Obes Surg. 2016; 26(8):1659-96. PMC: 6037181. DOI: 10.1007/s11695-016-2271-4. View

Cotton P, Eisen G, Aabakken L, Baron T, Hutter M, Jacobson B . A lexicon for endoscopic adverse events: report of an ASGE workshop. Gastrointest Endosc. 2010; 71(3):446-54. DOI: 10.1016/j.gie.2009.10.027. View

Zechmeister-Koss I, Huic M, Fischer S . The duodenal-jejunal bypass liner for the treatment of type 2 diabetes mellitus and/or obesity: a systematic review. Obes Surg. 2013; 24(2):310-23. DOI: 10.1007/s11695-013-1137-2. View

Homs M, Wahab P, Kuipers E, Steyerberg E, Grool T, Haringsma J . Esophageal stents with antireflux valve for tumors of the distal esophagus and gastric cardia: a randomized trial. Gastrointest Endosc. 2004; 60(5):695-702. DOI: 10.1016/s0016-5107(04)02047-4. View

de Jonge C, Rensen S, Verdam F, Vincent R, Bloom S, Buurman W . Impact of Duodenal-Jejunal Exclusion on Satiety Hormones. Obes Surg. 2015; 26(3):672-8. DOI: 10.1007/s11695-015-1889-y. View

de Jonge C, Rensen S, Koek G, Joosten M, Buurman W, Bouvy N . Endoscopic duodenal-jejunal bypass liner rapidly improves plasma parameters of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2013; 11(11):1517-20. DOI: 10.1016/j.cgh.2013.07.029. View

Betzel B, Koehestanie P, Homan J, Aarts E, Janssen I, de Boer H . Changes in glycemic control and body weight after explantation of the duodenal-jejunal bypass liner. Gastrointest Endosc. 2016; 85(2):409-415. DOI: 10.1016/j.gie.2016.07.027. View

10.

Stolbova S, Benes M, Petruzelkova L, Lebl J, Kolouskova S . For Debate: Should Bariatric Surgery be Performed in Children and Adolescents with Hypothalamic Obesity?. Pediatr Endocrinol Rev. 2017; 14(4):348-352. DOI: 10.17458/per.vol14.2017.SBP.FD.Bariatric. View

11.

Espinet Coll E, Nebreda Duran J, Lopez-Nava Breviere G, Ducons Garcia J, Rodriguez-Tellez M, Crespo Garcia J . Multicenter study on the safety of bariatric endoscopy. Rev Esp Enferm Dig. 2017; 109(5):350-357. DOI: 10.17235/reed.2017.4499/2016. View

12.

Uitdehaag M, Siersema P, Spaander M, Vleggaar F, Verschuur E, Steyerberg E . A new fully covered stent with antimigration properties for the palliation of malignant dysphagia: a prospective cohort study. Gastrointest Endosc. 2009; 71(3):600-5. DOI: 10.1016/j.gie.2009.09.023. View

13.

Escalona A, Yanez R, Pimentel F, Galvao M, Cardoso Ramos A, Turiel D . Initial human experience with restrictive duodenal-jejunal bypass liner for treatment of morbid obesity. Surg Obes Relat Dis. 2010; 6(2):126-31. DOI: 10.1016/j.soard.2009.12.009. View

14.

Sebastian S, Johnston S, Geoghegan T, Torreggiani W, Buckley M . Pooled analysis of the efficacy and safety of self-expanding metal stenting in malignant colorectal obstruction. Am J Gastroenterol. 2004; 99(10):2051-7. DOI: 10.1111/j.1572-0241.2004.40017.x. View

15.

. Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants. Lancet. 2016; 387(10026):1377-1396. PMC: 7615134. DOI: 10.1016/S0140-6736(16)30054-X. View

16.

Chou R, Aronson N, Atkins D, Ismaila A, Santaguida P, Smith D . AHRQ series paper 4: assessing harms when comparing medical interventions: AHRQ and the effective health-care program. J Clin Epidemiol. 2008; 63(5):502-12. DOI: 10.1016/j.jclinepi.2008.06.007. View

17.

de Jonge C, Rensen S, DAgnolo H, Bouvy N, Buurman W, Greve J . Six months of treatment with the endoscopic duodenal-jejunal bypass liner does not lead to decreased systemic inflammation in obese patients with type 2 diabetes. Obes Surg. 2013; 24(2):337-41. DOI: 10.1007/s11695-013-1154-1. View